TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: microvascular insulin-mediated dilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Total Improvement Score (TIS) ≥ 40 response
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Incidence of bone marrow suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: DHI Change in Scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Formation of stool
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Other symptoms related to defecation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Maximum Predicted Plasma Concentration (Cmax) of ATM and AVI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the Concentration-Time Curve (AUC) of ATM-AVI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Participants reporting Adverse Events (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Distance (6m) Visual Acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of cancers in people with HIV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Frequency of immunologic responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Safety of H1299 lung cancer cell lysate vaccines
Endpoint domain: Adverse events/effects
Primary endpoint: Feasibility of molecular profiling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mediterranean diet score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distant relapse-free survival (DRFS)
Endpoint domain: Mortality/survival
Primary endpoint: Annual bleeding Rate (ABRs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in Urine Protein Creatinine Ratio (UPCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of Participants Achieving Complete Remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Receipt of sexually transmitted infection (STI) testing
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Times having vaginal and anal sex without condoms
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Procedure-Emergent Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Procedure-Emergent Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Survival Follow-Up
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of participants discontinuing investigational medicinal product (IMP) due to an adverse event (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical Outcome using the Forgotten Joint Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in the proportion of active CD8+ T cells infiltrating the tumor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Pharmacodynamic (PD) response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical improvement in ulcerative colitis severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in LVEDV/BSA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants Experiencing Dose Limiting Toxicities (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Fusion Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: High climate impact menu item selected
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Total greenhouse gas emissions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Executive Function and Attention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Executive Function-Global Cognition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Executive Function-Working Memory
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Best overall response (BOR) of partial response (PR) or better
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Illicit opioid-use
Endpoint domain: Adverse events/effects
Primary endpoint: Quality of Recovery 15 survey score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Time to medication change or demonstrated BP control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in the Yale-Brown Obsessive Compulsive Scale (Y-BOCS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of OSCC or OPC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Average days to full return to duty clearance
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Percent of patients considered frail
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Local Recurrence Free Survival (LRFS)
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Participants who Achieve a Complete Renal Response (CRR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in total hip areal bone mineral density (aBMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Liver iron concentration (LIC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Severity of Treatment-emergent adverse events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants experiencing dose limiting toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Complete Remission (CR) Plus CR With Partial Hematologic Recovery (CRh) Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Hematologic outcomes
Primary endpoint: Modified Overall Response (mOR) Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Hematologic outcomes
Primary endpoint: Number Of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Achieving mPDAI Remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number and percentage of completed in-bed cycling/stepping sessions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: duration and percentage of in-bed cycling/stepping sessions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of cessations of in-bed cycling/stepping sessions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 3-month all-cause mortality
Endpoint domain: Mortality/survival
Primary endpoint: Between group change in total movement time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Between group change in time spent being sedentary
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Between group change in time being moderate to vigorous physical active (MVPA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average endothelial cell density (ECD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in relative abundance of microbial skin taxa and/or skin metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Fold difference in metabolic pathways associated with immune pathways
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Fold differences in metabolic pathways related to wound healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Patients using Multiple Pharmacies
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Rate of destructive behavior
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of participants who achieve global cure
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of Participants with POAF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants with PMI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants with ARDS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Participants with PPS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Time It Takes to Reach 90% of Asymptotic Level Performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Overall Mean Peak (Pupillary Response)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Speed of Learning to Perform a Behavioral Task
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Time to first occurrence of all-cause mortality
Endpoint domain: Mortality/survival
Primary endpoint: Time to first hospital readmission for cardiovascular causes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Liver transplant waiting list
Endpoint domain: Mortality/survival
Primary endpoint: Change in health status (KCCQ CSS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of Optimizer device- or procedure-related complications
Endpoint domain: Adverse events/effects
Primary endpoint: Availability of respiratory sinus arrhythmia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage Difference in PUSH Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of gene expression of identified species
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Incidence of confirmed VTE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Cartilage Strain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient-Reported Outcomes Measurement Information System (PROMIS) physical function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Single Assessment Numeric Evaluation (SANE) Scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: PH reading
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: stereoselective disposition of methadone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: disposition and pharmacodynamics of tizanidine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: No. of Participants Taking up Breast Cancer Screening at Three Months - Intention to Treat
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: No. of Participants Taking up Breast Cancer Screening at Three Months - Per Protocol
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: freedom from Major Adverse Events (MAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: proportion of subjects with non-inducible VT or no further ablation targets
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of elevated hs-TnT levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Stress hormone response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in bacterial count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of patients experiencing treatment-emergent adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Auditory speech perception
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Non-inferiority of CE-BCT compared with CE-MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: incidence of device- and/or procedure-related serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: reflective Total Nasal Symptom Score (rTNSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alignment Control Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Conversion rate
Endpoint domain: Mortality/survival
Primary endpoint: Columbia-Suicide Severity Rating Scale (C-SSRS) Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Mental health outcomes
Primary endpoint: Patient Health Questionnaire-9 Total Score and Question 9 Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: ATP bioluminescence tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Microbial cultures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Frequency of countable motor seizures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean Absorbed Dose (Gy) for the Whole Body
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Absorbed Dose (Gy) for Critical Non-liver Organs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effective Dose (Gy) for the Whole Body
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Daytime Insomnia Symptoms Scale (DISS)
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Effective residual concentration of posaconazole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acute Grade 3 or greater adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: 25% reduction in the volume of the rectum receiving 90% of the prescribed radiation dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: 90-day favorable clinical outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fasting Insulin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Clumsy-Well Coordinated
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Drowsy-Alert
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change in percent correct for treated sound
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Eyberg Child Behavior Inventory - Intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parenting Sense of Competence - Efficacy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: FASD Knowledge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean Activation of Frontostriatal and Prefrontal Brain Regions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: FLR growth rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LDL-cholesterol concentration change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Uptake of MAD
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Efficacy of MAD for treating mild-to-moderate OSA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in patient-reported symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Presence of moderate to severe Post-thrombotic Syndrome (PTS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Thrombosis burden
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change in Visual analog score (VAS) at 4 weeks
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change of range of motion of shoulders from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of Participants with Abscopal Response in Non-irradiated Target Lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Immediate adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: Delayed adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: Long-term safety of ST-920
Endpoint domain: Adverse events/effects
Primary endpoint: Systemic inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Modified Rankin Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Binocular photopic uncorrected visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum tolerated dose of ipilimumab
Endpoint domain: Adverse events/effects
Primary endpoint: Mechanical properties measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time course of blood thymidine kinase activity (TKa)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change from Baseline in objective cough frequency (8 hours)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change from Baseline in objective cough frequency (4 hours)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percent of correct comprehension questions for more social stories
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Percent of correct comprehension questions for less social stories
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Mean Change From Baseline in Weekly Urticaria Activity Score (UAS7)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change From Baseline in Weekly Itch Severity Score (ISS7)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change From Baseline in Weekly Hives Severity Score (HSS7)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of subjects with study wound deemed closed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Measurement of stigma experienced by pediatric oncology patients/survivors
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Measurement of stigma experienced by guardians/caregivers
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Primary Efficacy Endpoint (Drug-related)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Primary Safety Endpoint (Disease-related)
Endpoint domain: Adverse events/effects
Primary endpoint: True positive rate of CEM vs. MMG (Sensitivity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Accuracy of CEM vs. MMG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Re-operation rate in the Interventional Group
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Time of the first rescue analgesic request
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in Columbia-Suicide Severity Rating Scale (C-SSRS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Plasma Concentration of Fosigotifator
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ratio of overall wastage of injectable drugs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in Muscle Sympathetic Nerve Burst Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Prevalence of eye diseases causing visual disability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ranking of leading causes of visual impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to discontinuation of study treatment due to adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: Splenic response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of CDS alerts resulting in the prescription of a recommended medication
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of Time With Blood Sugar in Range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fraction of [14C] radioactivity excreted into urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fraction of [14C] radioactivity excreted into feces
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration-time curve of the analyte in plasma after intravenous administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration-time curve of the analyte in plasma after oral administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Days Outside the Home
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning